uniQure N.V. (NASDAQ:QURE) Expected to Post Quarterly Sales of $2.92 Million
Equities analysts expect that uniQure N.V. (NASDAQ:QURE) will announce $2.92 million in sales for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for uniQure N.V.’s earnings. The lowest sales estimate is $2.38 million and the highest is $3.59 million. uniQure N.V. reported sales of $1.82 million during the same quarter last year, which would suggest a positive year over year growth rate of 60.4%. The company is expected to announce its next earnings report on Thursday, August 24th.
According to Zacks, analysts expect that uniQure N.V. will report full-year sales of $2.92 million for the current financial year, with estimates ranging from $11.90 million to $17.47 million. For the next financial year, analysts forecast that the firm will post sales of $28.48 million per share, with estimates ranging from $18.53 million to $35.00 million. Zacks’ sales calculations are an average based on a survey of analysts that follow uniQure N.V..
uniQure N.V. (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.16. The company had revenue of $3.32 million during the quarter, compared to analyst estimates of $4.20 million. uniQure N.V. had a negative return on equity of 103.26% and a negative net margin of 223.38%.
A number of research analysts have recently commented on QURE shares. Cowen and Company reissued a “buy” rating on shares of uniQure N.V. in a report on Wednesday, May 24th. Oppenheimer Holdings, Inc. set a $17.00 target price on shares of uniQure N.V. and gave the stock a “buy” rating in a report on Tuesday, May 16th. Chardan Capital set a $13.00 target price on shares of uniQure N.V. and gave the stock a “buy” rating in a report on Sunday, July 23rd. ValuEngine raised shares of uniQure N.V. from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $8.00 target price on shares of uniQure N.V. in a report on Wednesday, April 12th. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $14.61.
In other uniQure N.V. news, insider Harald Petry sold 49,300 shares of the stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $6.02, for a total transaction of $296,786.00. Following the completion of the sale, the insider now owns 27,753 shares of the company’s stock, valued at approximately $167,073.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 173,460 shares of company stock valued at $1,042,986 in the last three months. Insiders own 0.64% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. FMR LLC increased its stake in shares of uniQure N.V. by 27.5% in the first quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock valued at $8,661,000 after buying an additional 323,345 shares during the period. Morgan Stanley increased its stake in shares of uniQure N.V. by 14.9% in the first quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock valued at $3,271,000 after buying an additional 73,418 shares during the period. Renaissance Technologies LLC increased its stake in shares of uniQure N.V. by 48.8% in the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock valued at $2,162,000 after buying an additional 122,700 shares during the period. P.A.W. Capital Corp bought a new stake in shares of uniQure N.V. during the first quarter valued at approximately $867,000. Finally, Paloma Partners Management Co increased its stake in shares of uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 74,605 shares during the period. 30.22% of the stock is owned by institutional investors.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.